Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a ...

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Geron Corporation's RYTELO gains FDA approval for Low-Risk MDS, with strong sales projections and promising Phase 3 study.

A loss-of-function mutation to the PTPN2 gene, commonly associated with autoimmune diseases, can make cells more susceptible ...

Comparator drugs in the analysis included Janus kinase (JAK) inhibitors such as tofacitinib (Xeljanz) and biologics with non-TNF targets, including abatacept (Orencia), tocilizumab (Actemra), and ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...